-
公开(公告)号：US20200093831A1
公开(公告)日：2020-03-26
申请号：US16695653
申请日：2019-11-26
发明人： John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号： A61K31/5375 , C07C229/22 , C07C229/08 , A61K31/4402 , A61K31/44 , C07C229/26 , C07C271/52 , C07C219/04 , C07C271/44 , A61K31/221 , C07F9/09 , A61K31/661 , A61K31/4406 , A61K31/223 , C07C205/37 , A61K31/27 , A61K31/265 , A61K31/40 , C07F9/12 , C07C323/58 , A61K31/4409 , A61K31/06 , A61K31/495 , A61K31/4453
摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
公开(公告)号：US20230100940A1
公开(公告)日：2023-03-30
申请号：US17840436
申请日：2022-06-14
发明人： John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号： A61K31/5375 , A61K31/4453 , A61K31/495 , A61K31/06 , A61K31/4409 , C07C323/58 , C07F9/12 , A61K31/40 , A61K31/265 , A61K31/27 , C07C205/37 , A61K31/223 , A61K31/4406 , A61K31/661 , C07F9/09 , A61K31/221 , C07C271/44 , C07C219/04 , C07C271/52 , C07C229/26 , A61K31/44 , A61K31/4402 , C07C229/08 , C07C229/22
摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
公开(公告)号：US11406642B2
公开(公告)日：2022-08-09
申请号：US16695653
申请日：2019-11-26
发明人： John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号： A61K31/5375 , A61K31/4453 , A61K31/495 , A61K31/06 , A61K31/4409 , C07C323/58 , C07F9/12 , A61K31/40 , A61K31/265 , A61K31/27 , C07C205/37 , A61K31/223 , A61K31/4406 , A61K31/661 , C07F9/09 , A61K31/221 , C07C271/44 , C07C219/04 , C07C271/52 , C07C229/26 , A61K31/44 , A61K31/4402 , C07C229/08 , C07C229/22 , C07D295/145 , C07D295/088 , C07D295/205 , C07D213/40 , C07D295/13
摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
公开(公告)号：US10548900B2
公开(公告)日：2020-02-04
申请号：US15451938
申请日：2017-03-07
发明人： John Gerard Geisler , Robert Alonso , Peter Anthony Crooks , Narsimha Reddy Penthala , Zaineb Albayati
IPC分类号： A61K31/535 , A61K31/5375 , A61K31/4453 , A61K31/495 , A61K31/06 , A61K31/221 , A61K31/223 , A61K31/265 , A61K31/27 , A61K31/40 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/661
摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
